

Skin Disease-Oriented Team

Clinical Research Treatment Flowchart

Clinical Research Manager:
Mehir Tharani

Clinical Research Coordinators:
Bao-An Huynh
Natalie Arechiga
Erin Palmer-Torrison
Anastasiia Reipolska

FIRST LINE RESECTABLE

STAGE 2

FIRST LINE, STAGE 3 NEOADJUVANT + ADJUVANT

FIRST LINE, METASTATIC OR UNRESECTABLE

UCI 25-17
 Adjuvant Pembrolizumab vs Biosimilar (Rollover Study)
 PI: Chow
 CRC: E. Palmar-Torrison
 Accrual: 2/5

UCI 25-17
 Adjuvant Pembrolizumab vs Biosimilar (Rollover Study)
 PI: Chow
 CRC: E. Palmar-Torrison
 Accrual: 2/5

UCI 25-77
*HLA-A*02:01-positive*
 Brenetafusp + Nivolumab vs. Opdualag (TCR-based T-cell engager)
 PI: Vaidya
 CRC: A. Reipolska
 Accrual: 0/5

EA6244
 WLE + SLN biopsy vs. WLE
 PI: Tran
 CRC: A. Reipolska
 Accrual: 0/15

UCI 24-123
 Fianlimab + Cemiplimab + Sx (Anti-LAG-3 + anti-PD-1 antibody)
 PI: Chow
 CRC: TBD
 Accrual: 0/35

UCI 25-128
 Fianlimab + Cemiplimab vs. Opdualag (Anti-LAG-3 + anti-PD-1 antibody)
 PI: Vaidya
 CRC: A. Reipolska
 Accrual: 2/7

UVEAL

UCI 25-78
 Neoadjuvant Darovasertib vs. Plaque brachytherapy or Enucleation
 PI: Vaidya
 CRC: B. Huynh
 Accrual: 0/5



RECURRENT WITH PREVIOUS CPI

UCI 24-112

Vusolimogene Oderparepvec (HSV-1)
+ Nivolumab **vs.**
Physician's Choice
PI: Tran
CRC: A. Reipolska
Accrual: 1/5

UCI 22-49

Pembrolizumab + Cyclophosphamide
(Anti-PD-1 antibody + Alkylation)
PI: Chow
CRC: B. Huynh
Accrual: 4/14

S2101

Nivolumab + Cabozantinib
(immunoMATCH: TMB + GEP)
PI: Vaidya
CRC: N. Arechiga
Accrual: 6/12

UCI 23-218

[212 Pb] VMT01 ± Nivolumab
PI: Srinivas
CRC: E. Palmer-Torrison
Accrual: 0/5

BASKET PHASE I TRIALS

UCI 24-113

BMS-686482
(CELMoD degrader IKZF transcription
factors)
PI: Chow
CRC: N. Arechiga
Accrual: 5/10
(Waitlist)

ETCTN 10572

Temozolomide (TMZ) + M1774
(Alkylator + ATR protein kinase
inhibitor)
PI: Dayyani
CRC: B. Huynh
Accrual: 1/10
Slot request

UCI 24-142

VET3-TGI (recombinant virus –
transgenes IL-12 + TGF-β inhibitor) ±
Atezolizumab
PI: Uchio
CRC: B. Huynh
Accrual: 2/4
(Waitlist)



NON INTERVENTIONAL TRIALS

UCI 19-135

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

PI: Yamamoto
CRC: Anastasiia R.
Accrual: 105/110

UCI 23-149

Multiphoton Microscopy Imaging as a Tool to Monitor Immune Activation Induced by Checkpoint Inhibitors

PI: Ganesan
Contact: Hira Rizwi
Accrual: 7/15

UCI 23-93

Assessment of ICOS as a Novel Biomarker to Determine Response and Resistance of Checkpoint Immunotherapy for Cutaneous Malignancies

PI: Tran
Target Accrual: 9/15



BASKET PHASE I TRIALS

UCI 24-142

VET3-TGI (recombinant virus – transgenes IL-12
+ TGF- β inhibitor) $\pm$ Pembrolizumab

PI: Uchio

CRC: B. Huynh

Accrual: 2/4

(Waitlist)

LOCALLY ADVANCED cSCC W/ PREVIOUS CPI

UCI 25-147
L19IL2 + L19TNF (Intratumoral)
PI: Yamamoto
CRC: TBD
Accrual: 0/5

BASKET PHASE I TRIALS

UCI 24-142
VET3-TGI (recombinant virus – transgenes IL-12 +
TGF- β inhibitor) $\pm$ Pembrolizumab
PI: Uchio
CRC: B. Huynh
Accrual: 2/4
(Waitlist)

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended



INTERVENTIONAL TRIALS

UCI 23-153
Topical HT-001 for Skin Toxicities w/EGFR Inhibitor
(Topical aprepitant)
PI: Smith
CRC: B. Huynh
Accrual: 2/16
Closed 6/18/26 d/t sponsor decision

UCI 25-08
Laser treatment for Stage 1 BCC
(10'l nm Nd:YAG laser)
PI: Zachary
CRC: TBD
Accrual: 0/10

UCI 25-57
Neoadjuvant Opdualag vs. Nivolumab for Resectable High-Risk BCC
PI: Vaidya
CRC: A. Reipolska
Accrual: 1/10

UCI 25-127
Biofield therapy for immunotherapy-related symptoms
PI: Kagramanov
CRC: Dr. Kagramanov
Accrual: 0/12

UCI 24-87
Methionine-Reduced Diet
PI: Arter
CRC: K. Buttigieg
Accrual: 2/25

NON-INTERVENTIONAL TRIALS

UCI 13-13
(IRB 2011-8494)
In-Vivo Non-Invasive Skin Imaging Using Multiphoton Microscopy and Multispectral Imaging
PI: Kelly
Accrual: 222/250

UCI 25-68
Understanding Barriers to Skin Cancer in AAPI
PI: Tran
Accrual: 17/75

UCI 26-102
Immune Checkpoint inhibition-related Cognitive Impairments
PI: Chan
CRC: TBD
Accrual: 0/18